Ultrasensitive antibody detection with PCR
Detecting disease when it matters
Enable Biosciences is a biotech company based in San Francisco, CA. We develop ultrasensitive antibody detection technologies for clinical diagnostics and research. Our powerful Antibody Detection by PCR (ADAP) platform is 1000-10000x more sensitive than standard immunoassays while being readily deployable in academic and clinical settings.
When you get sick, your immune system produces antibodies. Billions of tests are performed each year to detect these molecules as an indicator of disease. Enable Biosciences’ approach could help diagnose diseases like HIV and type 1 diabetes at an earlier, more easily treatable stage.
THE ADAP ADVANTAGE
Our platform uses DNA tags in a completely solution-phase immunoassay. This preserves the native antigen for detecting conformationally sensitive epitopes, like those often seen in autoantibody biomarkers.
AWARD WINNING TEAM
Enable’s technology platform was developed by scientists at Stanford and UC Berkeley. The team won the 2016 Stanford Predictive and Diagnostics Accelerator prize and the 2016 Harvard Business School New Ventures Competition (HBS NVC) for Northern California. We were a top 4 finisher at the global HBS NVC finals.
JOIN THE ENABLE TEAM!
“Stanford chemists have increased the likelihood of detecting these diseases via a test that is thousands of times more sensitive than current diagnostics.”
“Detecting diseases such as cancer in their earliest stages can make a huge difference in patient treatment, but it is often difficult to do. Now scientists report a new, simple method that could make early disease diagnosis much easier.”
“Researchers have developed a polymerase chain reaction (PCR) method for detecting antibodies that is 1,000 times as sensitive as enzyme-linked immunosorbent assay (ELISA), the gold standard test”
“A new technique to detect HIV and cancer developed by a team of Stanford chemists could save lives.”